Page last updated: 2024-09-04

carbapenems and fr 264205

carbapenems has been researched along with fr 264205 in 20 studies

Compound Research Comparison

Studies
(carbapenems)
Trials
(carbapenems)
Recent Studies (post-2010)
(carbapenems)
Studies
(fr 264205)
Trials
(fr 264205)
Recent Studies (post-2010) (fr 264205)
7,3551475,27720217184

Research

Studies (20)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's4 (20.00)24.3611
2020's16 (80.00)2.80

Authors

AuthorsStudies
Ge, Y; Juan, C; Oliver, A; Pérez, JL; Zamorano, L1
Alberti, S; Beceiro, A; Cabot, G; Juan, C; Moyá, B; Oliver, A; Zamorano, L1
Abbo, LM; Adachi, J; Aitken, SL; Araos, R; Arias, CA; Bonomo, RA; Jain, R; Lichtenberger, PN; Miller, WR; Munita, JM; Nigo, M; Perez, F; Rakita, R; Rosa, R; Shelburne, S; Shimose, LA; Tran, TT; Wanger, A1
Dubois, V; Jayol, A; Kieffer, N; Nordmann, P; Ortiz De La Rosa, JM; Poirel, L1
Gatermann, SG; Körber-Irrgang, B; Korte-Berwanger, M; Kresken, M; Pfennigwerth, N; Seifert, H1
Alcalde-Rico, M; Arias, CA; García, P; Khan, A; Martínez, JRW; Miller, WR; Moreno, MV; Munita, JM; Olivares-Pacheco, J; Rivas, L; Rojas, P; Wozniak, A1
Carratalà, J; Cuervo, G; González Laguna, M; Llop Talaveron, J; Padullés, A; Pérez-Recio, S; Ronda, M; Soldevila-Boixader, L; Tubau Quintano, MF1
Ju, YG; Lee, HJ; Lee, MG; Sohn, JW; Yim, HS; Yoon, YK1
Birgy, A; Bonacorsi, S; Courroux, C; Danjean, M; Gits-Muselli, M; Hobson, CA; Monjault, A1
Maseda, E; Suárez de la Rica, A1
Gill, CM; Nicolau, DP2
Carvalho, TN; Deglmann, RC; França, PHC; Hille, D; Kobs, VC; Melo, LH1
Ballesta, S; López, CE; López-Cerero, L; Pascual, A; Rojo-Martin, MD; Sánchez-Yebra, W1
Bogiel, T; Grabowska, M; Sękowska, A1
Chau, RWY; Chen, WT; DeRyke, CA; Ip, M; Karlowsky, JA; Khan, TK; Leung, SWM; Lob, SH; Motyl, MR; Sahm, DF; Seto, WH; Wong, QW; Woo, PCY; Young, K1
Chen, TY; Hsu, CK; Lai, CC; Shih, SC; Tang, HJ; Weng, TS1
Hsueh, PR; Ko, WC; Lee, YL1
Fujimori, T; Hagiya, H; Higashikage, A; Iio, K; Kakehi, A; Minabe, H; Okura, M; Otsuka, F; Yokoyama, Y1
Chen, WT; Cheng, MH; Hsieh, TC; Karlowsky, JA; Lu, HC; Motyl, MR; Sahm, DF; Siddiqui, F; Wise, MG; Young, K1

Reviews

2 review(s) available for carbapenems and fr 264205

ArticleYear
Controversies in the management of ESBL-producing Enterabacterales. Clinical Implications.
    Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia, 2022, Volume: 35 Suppl 3

    Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactamases; Carbapenems; Cephalosporins; Humans; Meropenem; Microbial Sensitivity Tests; Piperacillin, Tazobactam Drug Combination; Tazobactam

2022
Comparing novel antibiotics and carbapenems for complicated intra-abdominal infections: a systematic review and meta-analysis of randomized controlled trials.
    International journal of antimicrobial agents, 2023, Volume: 62, Issue:2

    Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamase Inhibitors; Carbapenems; Ceftazidime; Drug Combinations; Humans; Intraabdominal Infections; Randomized Controlled Trials as Topic; Tazobactam

2023

Other Studies

18 other study(ies) available for carbapenems and fr 264205

ArticleYear
Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains.
    Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:2

    Topics: Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Cephalosporins; Drug Resistance, Multiple, Bacterial; Humans; Isoelectric Focusing; Microbial Sensitivity Tests; Polymerase Chain Reaction; Pseudomonas aeruginosa; Pseudomonas Infections

2010
Pan-β-lactam resistance development in Pseudomonas aeruginosa clinical strains: molecular mechanisms, penicillin-binding protein profiles, and binding affinities.
    Antimicrobial agents and chemotherapy, 2012, Volume: 56, Issue:9

    Topics: Anti-Bacterial Agents; beta-Lactam Resistance; Binding Sites; Carbapenems; Ceftazidime; Cephalosporins; Cross Infection; Gene Expression; Humans; Imipenem; Kinetics; Microbial Sensitivity Tests; Penicillin-Binding Proteins; Protein Binding; Protein Isoforms; Pseudomonas aeruginosa; Pseudomonas Infections

2012
Multicenter Evaluation of Ceftolozane/Tazobactam for Serious Infections Caused by Carbapenem-Resistant Pseudomonas aeruginosa.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2017, 07-01, Volume: 65, Issue:1

    Topics: Adult; Aged; Anti-Bacterial Agents; Carbapenems; Cephalosporins; Female; Humans; Male; Middle Aged; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Tazobactam

2017
Acquisition of Extended-Spectrum β-Lactamase GES-6 Leading to Resistance to Ceftolozane-Tazobactam Combination in
    Antimicrobial agents and chemotherapy, 2019, Volume: 63, Issue:1

    Topics: Amino Acid Substitution; Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactam Resistance; beta-Lactamases; Carbapenems; Ceftazidime; Cephalosporins; Drug Combinations; Gene Expression; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam

2019
Dissemination of carbapenem-resistant Pseudomonas aeruginosa isolates and their susceptibilities to ceftolozane-tazobactam in Germany.
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:6

    Topics: Aged; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Cephalosporins; Cross Infection; Drug Resistance, Multiple, Bacterial; Germany; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Middle Aged; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam

2020
Real-World Performance of Susceptibility Testing for Ceftolozane/Tazobactam against Non-Carbapenemase-Producing Carbapenem-Resistant Pseudomonas aeruginosa.
    Antimicrobial agents and chemotherapy, 2022, 01-18, Volume: 66, Issue:1

    Topics: Anti-Bacterial Agents; Carbapenems; Cephalosporins; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam

2022
Ceftolozane/tazobactam for difficult-to-treat Gram-negative infections: A real-world tertiary hospital experience.
    Journal of clinical pharmacy and therapeutics, 2022, Volume: 47, Issue:7

    Topics: Adult; Anti-Bacterial Agents; Carbapenems; Cephalosporins; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Tazobactam; Tertiary Care Centers

2022
In vitro synergistic antimicrobial activity of a combination of meropenem, colistin, tigecycline, rifampin, and ceftolozane/tazobactam against carbapenem-resistant Acinetobacter baumannii.
    Scientific reports, 2022, 05-09, Volume: 12, Issue:1

    Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; Carbapenems; Cephalosporins; Colistin; Drug Combinations; Drug Synergism; Humans; Meropenem; Microbial Sensitivity Tests; Rifampin; Tazobactam; Tigecycline

2022
Evaluation of the inoculum effect of new antibiotics against carbapenem-resistant enterobacterales.
    Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2022, Volume: 28, Issue:11

    Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; Carbapenems; Cefiderocol; Humans; Imipenem; Meropenem; Tazobactam

2022
Phenotypic and genotypic profile of ceftolozane/tazobactam-non-susceptible, carbapenem-resistant Pseudomonas aeruginosa.
    The Journal of antimicrobial chemotherapy, 2022, 12-23, Volume: 78, Issue:1

    Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamases; Carbapenems; Cefepime; Ceftazidime; Cephalosporins; Drug Combinations; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam

2022
Carbapenem-resistant Pseudomonas aeruginosa: an assessment of frequency of isolation from ICU versus non-ICU, phenotypic and genotypic profiles in a multinational population of hospitalized patients.
    Antimicrobial resistance and infection control, 2022, 11-30, Volume: 11, Issue:1

    Topics: Carbapenems; Cefepime; Ceftazidime; Phenotype; Pseudomonas aeruginosa; Tazobactam

2022
Evaluation of in-vitro susceptibility of ß-lactam-resistant Gram-negative bacilli to ceftazidime-avibactam and ceftolozane-tazobactam from clinical samples of a general hospital in southern Brazil.
    Revista da Sociedade Brasileira de Medicina Tropical, 2023, Volume: 56

    Topics: Anti-Bacterial Agents; beta-Lactamases; Brazil; Carbapenems; Ceftazidime; Cephalosporins; Drug Combinations; Gram-Negative Bacteria; Hospitals, General; Klebsiella pneumoniae; Lactams; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Tazobactam

2023
Evaluation of three commercial methods of susceptibility testing for ceftolozane/tazobactam against carbapenem-resistant Pseudomonas aeruginosa.
    Enfermedades infecciosas y microbiologia clinica (English ed.), 2023, Volume: 41, Issue:10

    Topics: Anti-Bacterial Agents; Carbapenems; Cross Infection; Humans; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam

2023
Satisfactory In Vitro Activity of Ceftolozane-Tazobactam against Carbapenem-Resistant
    Medicina (Kaunas, Lithuania), 2023, Mar-07, Volume: 59, Issue:3

    Topics: Anti-Bacterial Agents; Anti-Infective Agents; Carbapenems; Cephalosporins; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Humans; Klebsiella pneumoniae; Pseudomonas aeruginosa; Tazobactam

2023
Carbapenem resistance among Gram-negative isolates collected from patients in ICU and non-ICU hospital wards in Hong Kong: SMART 2017-2020.
    Journal of global antimicrobial resistance, 2023, Volume: 33

    Topics: Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Ertapenem; Escherichia coli; Hong Kong; Humans; Imipenem; Intensive Care Units; Meropenem; Pseudomonas aeruginosa; Tazobactam

2023
In vitro activities of ceftazidime-avibactam, ceftolozane-tazobactam, meropenem-vaborbactam and other comparators against Pseudomonas aeruginosa isolates with discrepant resistance to carbapenems: Data from the Antimicrobial Testing Leadership and Surveil
    International journal of antimicrobial agents, 2023, Volume: 62, Issue:2

    Topics: Anti-Bacterial Agents; Anti-Infective Agents; Azabicyclo Compounds; beta-Lactamases; Carbapenems; Ceftazidime; Cephalosporins; Doripenem; Humans; Imipenem; Leadership; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam

2023
Susceptibility of ceftolozane/tazobactam against multidrug-resistant and carbapenem-resistant Pseudomonas aeruginosa.
    The new microbiologica, 2023, Volume: 46, Issue:2

    Topics: Anti-Bacterial Agents; Carbapenems; Cephalosporins; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam

2023
Temporal and geographical prevalence of carbapenem-resistant Pseudomonas aeruginosa and the in vitro activity of ceftolozane/tazobactam and comparators in Taiwan-SMART 2012-2021.
    Journal of global antimicrobial resistance, 2023, Volume: 34

    Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; Carbapenems; Enterobacteriaceae; Humans; Prevalence; Pseudomonas aeruginosa; Pseudomonas Infections; Taiwan; Tazobactam

2023